85 related articles for article (PubMed ID: 1515880)
1. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens.
Seiden MV; Elias A; Ayash L; Hunt M; Eder JP; Schnipper LE; Frei E; Antman KH
Bone Marrow Transplant; 1992 Jul; 10(1):57-63. PubMed ID: 1515880
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
[TBL] [Abstract][Full Text] [Related]
3. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
Crilley P; Topolsky D; Styler MJ; Bernstein E; Resnick K; Mullaney R; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1995 Mar; 15(3):361-5. PubMed ID: 7599559
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
Dimopoulou I; Galani H; Dafni U; Samakovii A; Roussos C; Dimopoulos MA
Cancer; 2002 Jan; 94(2):452-8. PubMed ID: 11900231
[TBL] [Abstract][Full Text] [Related]
6. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; McCauley M; Mazanet R; Schnipper L; Frei E; Antman KH
Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
[TBL] [Abstract][Full Text] [Related]
8. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study.
Saez RA; Slease RB; Strnad C; Selby GB; Confer DL; Epstein RB
Bone Marrow Transplant; 1995 Oct; 16(4):507-14. PubMed ID: 8528165
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.
Stiff PJ; Bayer R; Tan S; Camarda M; Sosman J; Peace D; Kinch L; Rad N; Loutfi S
Clin Cancer Res; 1995 Dec; 1(12):1495-502. PubMed ID: 9815949
[TBL] [Abstract][Full Text] [Related]
12. Busulfan-containing pre-transplant regimens for the treatment of solid tumors.
Ghalie R; Reynolds J; Valentino LA; Manson S; Korenblit AD; Feingold JM; Adler SS; Pruett J; Kaizer H
Bone Marrow Transplant; 1994 Sep; 14(3):437-42. PubMed ID: 7994269
[TBL] [Abstract][Full Text] [Related]
13. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
15. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F
Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue.
Spitzer TR; Cirenza E; McAfee S; Foelber R; Zarzin J; Cahill R; Mazumder A
Bone Marrow Transplant; 1995 Apr; 15(4):537-42. PubMed ID: 7655378
[TBL] [Abstract][Full Text] [Related]
17. High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors.
Broun ER; Nichols CR; Tricot G; Loehrer PJ; Williams SD; Einhorn LH
Bone Marrow Transplant; 1991 Jan; 7(1):53-6. PubMed ID: 1646050
[TBL] [Abstract][Full Text] [Related]
18. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
Spitzer TR; Cottler-Fox M; Torrisi J; Cahill R; Greenspan A; Lynch M; Deeg HJ
Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome.
Rubin CM; Mick R; Johnson FL
Bone Marrow Transplant; 1996 Sep; 18(3):533-40. PubMed ID: 8879614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
